AstraZeneca (AZN) Confirms FDA Partial Clinical Hold Placed on Patient Recruitment for MEDI4736 Trial in HNSCC; Issues Commentary
Tweet Send to a Friend
AstraZeneca (NYSE: AZN) issued the following statement following news that recruitment for its study of MEDI4736 (Durvaluma) in head and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
